The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
 
Debashis Sarker
Honoraria - Bayer; Bayer; Bayer; Bayer; Ipsen; Ipsen; Ipsen; Ipsen; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I)
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Eisai (I); Eisai (I); Eisai (I); Eisai (I); Ipsen (I); Ipsen (I); Ipsen (I); Ipsen (I); Novartis; Novartis; Novartis; Novartis
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; ipsen; ipsen; ipsen; ipsen; MiNA Therapeutics; MiNA Therapeutics; MiNA Therapeutics; MiNA Therapeutics
 
Mikael Sodergren
Research Funding - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); Amgen (I); Amgen (I); Amgen (I); Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I); Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Bayer; Bayer; Bayer; Bayer; Biosceptre; Biosceptre; Biosceptre; Biosceptre; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Cybrexa Therapeutics; Cybrexa Therapeutics; Cybrexa Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Ellipses Pharma; Ellipses Pharma; Ellipses Pharma; Karus Therapeutics; Karus Therapeutics; Karus Therapeutics; Karus Therapeutics; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis; Octimet; Octimet; Octimet; Octimet; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Speakers' Bureau - Novartis; Novartis; Novartis; Novartis
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst); Named on patent of use of PARP inhibitor rucaparib (Inst); Named on patent of use of PARP inhibitor rucaparib (Inst); Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology
 
Bristi Basu
Consulting or Advisory Role - Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Baxter; Baxter; Baxter; Baxter; Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst)
Research Funding - Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bayer Health; Bayer Health; Bayer Health; Bayer Health
 
Tim Meyer
Consulting or Advisory Role - Beigene; Beigene; Beigene; Beigene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; BTG; BTG; BTG; BTG; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; MSD; MSD; MSD; MSD; Tarveda Therapeutics; Tarveda Therapeutics; Tarveda Therapeutics; Tarveda Therapeutics
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BTG (Inst); BTG (Inst); BTG (Inst); BTG (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
 
Kai-Wen Huang
Research Funding - MINA Therapeutics; MINA Therapeutics; MINA Therapeutics; MINA Therapeutics
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Other Relationship - Genmab; Genmab; Genmab; Genmab
 
Duncan Spalding
No Relationships to Disclose
 
Yuk Ting Ma
No Relationships to Disclose
 
Daniel H. Palmer
No Relationships to Disclose
 
Cheng Ean Chee
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer
 
David James Pinato
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Mina Therapeutics; Mina Therapeutics; Mina Therapeutics; Mina Therapeutics
Speakers' Bureau - Bayer; Bayer; Bayer; Bayer; ViiV Healthcare; ViiV Healthcare; ViiV Healthcare; ViiV Healthcare
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Vikash Reebye
Employment - Mina THERAPEUTICS; Mina THERAPEUTICS; Mina THERAPEUTICS; Mina THERAPEUTICS
Stock and Other Ownership Interests - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS
 
Daniel McVeigh
Employment - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS
 
Nina Raulf
Employment - MinA THERAPEUTICS; MinA THERAPEUTICS; MinA THERAPEUTICS; MinA THERAPEUTICS
 
Jenni Vasara
Employment - Mina THERAPEUTICS; Mina THERAPEUTICS; Mina THERAPEUTICS; Mina THERAPEUTICS
 
Pinelopi Andrikakou
Research Funding - MiNA Therapeutics; MiNA Therapeutics; MiNA Therapeutics; MiNA Therapeutics
 
Robert Habib
Employment - Mina THERAPEUTICS; Mina THERAPEUTICS; Mina THERAPEUTICS; Mina THERAPEUTICS
Stock and Other Ownership Interests - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS
 
David Blakey
Employment - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS
Stock and Other Ownership Interests - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS
 
Nagy A. Habib
Employment - MINA THERAPEUTICS (I); MINA THERAPEUTICS (I); MINA THERAPEUTICS (I); MINA THERAPEUTICS (I)
Stock and Other Ownership Interests - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS
Research Funding - MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS; MINA THERAPEUTICS